EUVIMEDEUVIMED entdecken
Crossref

Efficacy of Nivolumab and Pembrolizumab in Platinum-sensitive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Gai Yamashita, Isaku Okamoto, Tatsuya Ito, Kunihiko Tokashiki, Takuro Okada, Kiyoaki Tsukahara

Anticancer Research · 2023

DOI: 10.21873/anticanres.16550 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2023. Verfasst von Gai Yamashita und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan. Hauptthemen laut MEDLINE: Nivolumab, Neoplasm Recurrence, Local, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabNeoplasm Recurrence, LocalSquamous Cell Carcinoma of Head and NeckHead and Neck NeoplasmsAntibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsNeoplasm MetastasisPlatinum CompoundsHumansMaleFemaleMiddle AgedAgedTreatment Outcome

Stichwörter der Autor:innen

Nivolumabpembrolizumabplatinum sensitiverecurrent or metastatic head and neck squamous cell carcinoma

Substanzen

NivolumabpembrolizumabAntibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsPlatinum Compounds

Autor:innen und Institutionen

  • Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
  • Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan isaku@tokyo-med.ac.jp.

Zitieren

APA

Yamashita, G., Okamoto, I., Ito, T., Tokashiki, K., Okada, T., & Tsukahara, K. (2023). Efficacy of Nivolumab and Pembrolizumab in Platinum-sensitive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Anticancer Research. https://doi.org/10.21873/anticanres.16550

Vancouver

Yamashita G, Okamoto I, Ito T, Tokashiki K, Okada T, Tsukahara K. Efficacy of Nivolumab and Pembrolizumab in Platinum-sensitive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Anticancer Research. 2023. doi:10.21873/anticanres.16550

BibTeX
@article{Yamashita2023,
  author = {Yamashita, Gai and Okamoto, Isaku and Ito, Tatsuya and Tokashiki, Kunihiko and Okada, Takuro and Tsukahara, Kiyoaki},
  title = {Efficacy of Nivolumab and Pembrolizumab in Platinum-sensitive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma},
  journal = {Anticancer Research},
  year = {2023},
  doi = {10.21873/anticanres.16550}
}
Kostenlos starten →